Containing Solid Synthetic Polymers Patents (Class 424/462)
-
Patent number: 8128957Abstract: The present invention relates to a modified release composition of at least one form of tramadol which is a delayed and extended release composition for oral administration suitable for once daily dosing. That composition comprises a core comprising at least one form of tramadol selected from the group consisting of tramadol, racemic mixtures thereof, enantiomers thereof, pharmaceutically acceptable salts thereof, and combinations thereof in combination with a pharmaceutically acceptable excipient. That composition further comprises a modified release coating which substantially surrounds said core. The compositions of the invention provide delayed and extended release of said at least one form of tramadol such that the mean plasma concentration of the at least one form of tramadol reaches a therapeutically effective level at a time which is after at least about 3 hours after first administration.Type: GrantFiled: September 3, 2004Date of Patent: March 6, 2012Assignee: Valeant International (Barbados) SRLInventors: Pawan Seth, Paul J. Maes
-
Patent number: 8124654Abstract: Novel diterpene compounds, in particular, hypoestoxide-related compounds, are provided in pure form or as contained in the native plant source, for treatment and prophylaxis of cancer, inflammatory diseases, hyperlipidemias, malaria, and diabetes mellitus. Embodiments also pertain to methods for using the hypoestoxide-related compounds to treat various diseases and symptoms associated with those diseases.Type: GrantFiled: November 11, 2008Date of Patent: February 28, 2012Assignee: Immune Modulation, Inc.Inventors: Howard B. Cottam, Emmanuel A. Ojo-Amaize, Emeka J. Nchekwube, Olusola A. Oyemade, Donna G. Nchekwube
-
Patent number: 8097279Abstract: A matrix formulation for a soft chewable capsule is provided which includes a gel-forming composition, a plasticizer, a polymer modifier and water. The polymer modifier may be a carboxylic acid or other organic compound that alters the physical and/or chemical properties of the capsule formulation. A chewable soft capsule is also provided, having enhanced organo-leptic and processing properties. An active material may be delivered to a user using this dosage form. A method of forming the chewable soft capsule is also provided.Type: GrantFiled: April 24, 2003Date of Patent: January 17, 2012Assignee: Banner Pharmacaps Inc.Inventors: EmadEldin M. Hassan, Warren W. Kindt, Roger E. Gordon
-
Patent number: 8084045Abstract: The present invention relates to novel pharmaceutical formulations based on stable, fluid aqueous colloidal suspensions for the prolonged release of active principle(s), particularly protein active principle(s), and to the applications, especially therapeutic applications, of these formulations. The object of the invention is to propose a fluid pharmaceutical formulation for the prolonged release of active principle(s) that makes it possible, after parenteral injection, to increase significantly the in vivo release time of a therapeutic protein while at the same time reducing the plasma concentration peak of the active protein, said formulation furthermore being stable on storage and also being biocompatible, biodegradable, non-toxic and non-immunogenic and having a good local tolerance.Type: GrantFiled: November 19, 2004Date of Patent: December 27, 2011Assignee: Flamel TechnologiesInventors: Gauthier Pouliquen, Olivier Soula, Rémi Meyrueix, Florence Nicolas
-
Publication number: 20110311620Abstract: The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors.Type: ApplicationFiled: June 15, 2011Publication date: December 22, 2011Applicant: Takeda Pharmaceuticals North America, Inc.Inventors: Rajneesh Taneja, Vijay Gupte, Majid Vakilynejad
-
Publication number: 20110287096Abstract: Oral dosage forms for basic amine drugs, the dosage forms having a gastro-retentive component and a non gastro-retentive component. These dosage forms are capable of providing both IR and SR release rates for these drugs. In addition, they provide for release of the drug in the stomach and/or intestine of a mammal to which such dosage forms are administered. Such dosage forms include tablets and capsules. Such dosage forms provide improved bioavailability of otherwise poorly bioavailable basic amine drugs.Type: ApplicationFiled: May 18, 2011Publication date: November 24, 2011Applicant: ABON PHARMACEUTICALS, LLCInventors: Sudhir GORUKANTI, Yanming Zu, Phanidhara Kotamraj, Karunakar Neelam, Salah U. Ahmed
-
Publication number: 20110287097Abstract: Controlled release pharmaceutical compositions comprising ropinirole or pharmaceutically acceptable salts thereof, wherein embodiments have ropinirole embedded in a matrix comprising one or more polymers, and the composition in monolithic form or in multiparticulate form.Type: ApplicationFiled: August 14, 2008Publication date: November 24, 2011Applicants: DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES LIMITEDInventors: Hemanth Prakash Joshi, Narayanan Badri Vishwanathan
-
Publication number: 20110223247Abstract: Disclosed is a pharmaceutical composition for release control comprising a plurality of particles for release control. The plurality of particles for release control comprise a core material containing methylphenidate and a polymer coating layer for release control formed on the core material. The plurality of particles for release control are divided into two or more groups based on the average thickness of the polymer coating layer for release control. The particle groups are identical in terms of the composition of the polymer in the polymer coating layer, but are different in terms of the average thickness of the coated layer. The pharmaceutical composition for release control according to the present invention may control the release pattern of methylphenidate contained in the core material as desired, and can be used as an oral formulation in a variety of forms such as orally disintegrating tablets, etc.Type: ApplicationFiled: November 6, 2009Publication date: September 15, 2011Applicant: SAMYANG CORPORATIONInventors: Sang Yeob Park, Hojin Chung, Chaul Min Pai
-
Patent number: 7999005Abstract: An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.Type: GrantFiled: November 25, 2008Date of Patent: August 16, 2011Assignee: Schering-Plough Animal Health CorporationInventors: Chung Shih, Thomas J. Kennedy, Peter James Knight, Daniel S. Robins, Zezhi Jesse Shao
-
Publication number: 20110165234Abstract: A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.Type: ApplicationFiled: March 18, 2011Publication date: July 7, 2011Applicant: ANDRX PHARMACEUTICALS, LLCInventors: Manesh Dixit, Xiu-Xiu Cheng, Avinash Nangia, Chin Ming Chen
-
Patent number: 7897555Abstract: Microcapsules for use in liquid detergents having a core and a polyelectrolyte complex shell in the form of a semipermeable membrane comprising a particulate permeability-regulator. The invention also relates to a process for making the microcapsules and liquid detergents comprising said microcapsules.Type: GrantFiled: July 28, 2004Date of Patent: March 1, 2011Assignee: The Procter & Gamble CompanyInventors: Walter August Maria Broeckx, Eva Martin Del Valle
-
Publication number: 20100285120Abstract: A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.Type: ApplicationFiled: July 19, 2010Publication date: November 11, 2010Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yohko Akiyama, Takashi Kurasawa, Hiroto Bando, Naoki Nagahara
-
Patent number: 7803773Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.Type: GrantFiled: September 29, 2008Date of Patent: September 28, 2010Assignee: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Stefanie Decker
-
Patent number: 7767708Abstract: An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.Type: GrantFiled: November 1, 1999Date of Patent: August 3, 2010Assignee: Schering-Plough Animal Health Corp.Inventors: Shih Chung, Thomas J. Kennedy, Peter James Knight, Daniel S. Robins, Zezhi Jesse Shao
-
Patent number: 7759312Abstract: Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent.Type: GrantFiled: July 11, 2008Date of Patent: July 20, 2010Assignee: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Stefanie Decker
-
Patent number: 7749537Abstract: A method of forming a tablet includes the steps of pre-blending an active pharmaceutical ingredient susceptible to tackiness and a blending additive with a first mixing effort to form a pre-blend mixture, wherein the first mixing effort and a second mixing effort, resulting from mixing at least one excipient with the pre-blend mixture, form a blend suitable for direct compression and compressing the blend to form the tablet. One way of achieving the first mixing effort is to pre-blend for an extended period of time. The method allows for directly compressing the blend without the need for a granulation step or roller compression. One such active pharmaceutical ingredient susceptible to tackiness is ibuprofen.Type: GrantFiled: October 1, 2007Date of Patent: July 6, 2010Assignee: SCOLR Pharma, Inc.Inventors: Michael Hite, Cathy Federici, Alan Brunelle, Stephen Turner
-
Patent number: 7740881Abstract: Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37° C. of from about 12.5% to about 42.5% (by wt) opioid released after 1 hour, from about 25% to about 65% (by wt) opioid released after 2 hours, from about 45% to about 85% (by wt) opioid released after 4 hours, and greater than about 60% (by wt) opioid released after 8 hours, the in-vitro release rate being substantially independent of pH and chosen such that the peak plasma level of said opioid analgesic obtained in-vivo occurs from about 2 to about 8 hours after administration of the dosage form.Type: GrantFiled: July 24, 2000Date of Patent: June 22, 2010Assignee: Purdue Pharma LPInventors: Richard Sackler, Robert Kaiko, Paul Goldenheim
-
Publication number: 20100086589Abstract: An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.Type: ApplicationFiled: December 3, 2009Publication date: April 8, 2010Inventors: Thomas FRIEDL, Rolf-Stefan Brickl
-
Publication number: 20100047342Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.Type: ApplicationFiled: July 30, 2009Publication date: February 25, 2010Applicant: ADAMAS PHARMACEUTICALS, INC.Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
-
Publication number: 20100047343Abstract: A multi-particulate pharmaceutical composition of rapid release particles and controlled release particles comprising tramadol or a salt thereof is provided. The composition provides a rapid and controlled release of tramadol or a salt thereof in a substantially pH independent manner after oral administration to a subject. The composition can be included in a capsule, caplet, sachet, or other solid dosage form adapted to retain and then release solid pharmaceutical compositions.Type: ApplicationFiled: October 29, 2009Publication date: February 25, 2010Applicant: The University of KansasInventors: John L. Haslam, Roger A. Rajewski
-
Patent number: 7618649Abstract: A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant, e.g. pseudoephedrine sulfate and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2% of desloratadine decomposition products is disclosed. A solid composition comprising an anti-allergic effective amount of desloratadine and at least one, and preferably two pharmaceutically acceptable antioxidants is also disclosed.Type: GrantFiled: November 3, 2003Date of Patent: November 17, 2009Assignee: Schering CorporationInventor: Wing-Kee Philip Cho
-
Publication number: 20090263478Abstract: Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions.Type: ApplicationFiled: July 9, 2009Publication date: October 22, 2009Inventors: Kristin Arnold, David F. Erkoboni, Rakeshkumar K. Lad, Siva Rama K. Nutalapati, Zhongshui Yu
-
Publication number: 20090258066Abstract: The present invention is directed to pharmaceutical compositions, and methods of making such compositions, comprising microparticles containing a weakly basic drug core, a layer of alkaline buffer, and a controlled-release coating. The present invention is also directed to pharmaceutical dosage forms, including orally disintegrating tablets, conventional tablets, and capsules, and methods for their preparation.Type: ApplicationFiled: April 15, 2009Publication date: October 15, 2009Inventors: Gopi VENKATESH, Phillip J. Stevens, Jin-Wang Lai
-
Publication number: 20090220593Abstract: The present invention relates to multiple unit extended release dosage forms of quetiapine for oral administration, wherein each unit comprises a core containing quetiapine and one or more of pharmaceutically acceptable excipients coated with a rate-controlling coating and process for the preparation thereof.Type: ApplicationFiled: January 28, 2009Publication date: September 3, 2009Inventors: Inder GULATI, Rajan Kumar Verma, Rajeev Singh Raghuvanshi
-
Publication number: 20090208570Abstract: The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms.Type: ApplicationFiled: March 28, 2007Publication date: August 20, 2009Inventors: Prashant Manohar Mandaogade, Venkatesh Madhavacharya Joshi, Saurabh Srivastava, Vinayak Dinkar Kadam, Girish Kumar Jain
-
Patent number: 7560098Abstract: Polymers containing one or more crylene moieties attached to the polymer backbone, sunscreen compositions including a mixture of a photoactive compound and a polymer containing one or more crylene moieties attached to the polymer backbone are described herein. Also disclosed are methods for stabilizing a sunscreen composition and methods of filtering out ultra-violet light from a substrate by the addition of one or more of the foregoing polymers, and methods of waterproofing and forming a film with one or more of the foregoing polymer are described herein.Type: GrantFiled: October 15, 2004Date of Patent: July 14, 2009Assignee: Hallstar Innovations Corp.Inventors: Craig A. Bonda, Anna B. Pavlovic
-
Publication number: 20090175935Abstract: The present invention relates to solid oral pharmaceutical compositions of duloxetine, process for preparing such compositions and method of using such compositions. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core comprising duloxetine, optional separating coat and an enteric coat, wherein the enteric coat comprises methacrylic acid copolymer.Type: ApplicationFiled: August 10, 2007Publication date: July 9, 2009Applicant: TORRENT RESEARCH LTD.Inventors: Umesh Setty, Rakesh Kiritbhai Sheth, Sujay Kamalakar Rajhans, Pravin Meghraj Bhutada, Hasmukh Mathurbhai Patel
-
Patent number: 7550134Abstract: Polymers containing one or more fluorene moieties attached to the polymer backbone, sunscreen compositions including a mixture of a photoactive compound and a polymer containing one or more fluorene moieties attached to the polymer backbone are described herein. Also disclosed are methods for stabilizing a sunscreen composition and methods of filtering out ultra-violet light from a substrate by the addition of one or more of the foregoing polymers, and methods of waterproofing and forming a film with one or more of the foregoing polymer are described herein.Type: GrantFiled: October 15, 2004Date of Patent: June 23, 2009Assignee: Hallstar Innovations Corp.Inventors: Craig A. Bonda, Anna B. Pavlovic
-
Publication number: 20090068260Abstract: The present invention provides extended release pharmaceutical compositions of a beta blocker such as, but not limited to, metoprolol succinate as the active ingredient, optionally also comprising a diuretic such as but not limited to hydrochlorothiazide, and methods of preparing such extended release pharmaceutical compositions.Type: ApplicationFiled: May 29, 2008Publication date: March 12, 2009Inventors: Tomer Gold, Benny Moshe, Ronny Reinberg
-
Publication number: 20090053308Abstract: The present invention relates to a controlled release capsule preparation for oral administration, which contains (i) a granule containing a physiologically active substance which is a compound represented by the formula: wherein n is an integer of 1 to 3, and Ar is an aromatic ring optionally having substituent(s), or a salt thereof, and a hydrophilic polymer, and coated with an enteric coating agent and the like, and (ii) a fluidizer. According to the present invention, a controlled release composition for oral administration of an imidazole derivative, which has steroid C17,20-lyase inhibiting activity and which has remarkably improved sustainability of the blood concentration, is provided.Type: ApplicationFiled: March 3, 2006Publication date: February 26, 2009Applicant: Takeda Pharmaceutical Company LimitedInventors: Hajime Ishida, Yukihiro Nomura
-
Publication number: 20090017113Abstract: Duloxetine pellets having an enteric coating containing a polymethacrylate polymer can be formed with desirable release rates/profile and stability.Type: ApplicationFiled: July 11, 2008Publication date: January 15, 2009Inventors: Niels J. Osinga, Dirk Pamperin
-
Publication number: 20080317846Abstract: A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need at different times during the dosing period, i.e., mimicking the circadian rhythm and severity/manifestation of gastric acid secretion (and/or midnight gerd), predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.Type: ApplicationFiled: July 11, 2008Publication date: December 25, 2008Inventors: Phillip J. Percel, Nehal H. Vyas, Krishna S. Vishnupad, Gopi M. Venkatesh
-
Patent number: 7452868Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.Type: GrantFiled: March 10, 2006Date of Patent: November 18, 2008Assignee: Indevus Pharmaceuticals, Inc.Inventors: Petr Kuzma, Stephanie Decker
-
Patent number: 7435715Abstract: Microcapsules for use in liquid detergents having a core and a polyelectrolyte complex shell in the form of a semipermeable membrane capable of withstanding a force before bursting of from about 20 mN to about 20,00 N and having a density of from about 900 Kg/m3 to about 1,300 Kg/m3 at 25° C. The invention also relates to a process for making the microcapsules and liquid detergents comprising said microcapsules.Type: GrantFiled: July 28, 2004Date of Patent: October 14, 2008Assignee: The Procter & Gamble CompanyInventors: Walter August Maria Broeckx, Roger Jeffrey Jones
-
Patent number: 7431944Abstract: Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release profile, the dosage forms eliminate the need for a patient to carry an additional dose for ingestion during the day. The dosage forms and methods provided are useful in administering methylphenidate and pharmaceutically acceptable salts thereof, which generally require one or more doses throughout the day.Type: GrantFiled: June 10, 2003Date of Patent: October 7, 2008Assignee: Celgene CorporationInventors: Atul M. Mehta, Andrew L. Zeitlin, Maghsoud M. Dariani
-
Publication number: 20080226712Abstract: The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions.Type: ApplicationFiled: May 21, 2008Publication date: September 18, 2008Applicant: NYCOMED GmbHInventors: Rango Dietrich, Hartmut Ney
-
Publication number: 20080226711Abstract: The present invention relates to solid oral pharmaceutical compositions of duloxetine, process for preparing such compositions and method of using such compositions. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core comprising duloxetine, optional separating coat and an enteric coat.Type: ApplicationFiled: March 11, 2008Publication date: September 18, 2008Applicant: TORRENT PHARMACEUTICALS LTD.Inventors: Sheth Rakesh K., Setty Umesh, Patel Hasmukh M.
-
Publication number: 20080166405Abstract: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist.Type: ApplicationFiled: March 14, 2008Publication date: July 10, 2008Inventor: Atul M. Mehta
-
Patent number: 7387791Abstract: This invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal tract after oral administration.Type: GrantFiled: July 13, 2004Date of Patent: June 17, 2008Assignee: Oradel Medical Ltd.Inventors: Guru V. Betageri, Milton B. Yatvin
-
Patent number: 7332160Abstract: The present invention relates to medical devices that are to be implanted or inserted into the body of a patient for the purpose of removing undesired body tissues. In one embodiment of the invention the medical device comprises a body tissue removal agent for removing undesired body tissue simultaneously with or prior to treatment of body tissue that is in proximity to the undesired body tissue with a biologically active material. Such biologically active material may facilitate regeneration of the body tissue that was removed or may prevent the recurrence of the undesired body tissue.Type: GrantFiled: July 12, 2002Date of Patent: February 19, 2008Assignee: Boston Scientific Scimed, Inc.Inventors: Toby Freyman, Wendy Naimark
-
Patent number: 7316818Abstract: This invention comprises pharmaceutical compositions for administering a polycyclic, aromatic, antioxidant or anti-inflammatory compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver polycyclic, aromatic, antioxidant or anti-inflammatory compounds to the gastrointestinal tract after oral administration.Type: GrantFiled: November 30, 2004Date of Patent: January 8, 2008Assignee: Oradel Medical Ltd.Inventor: Milton Yatvin
-
Patent number: 7259139Abstract: The invention relates to preparations that are useful in maintaining mammalian blood glucose concentrations. These preparations contain insulin, and a polymeric matrix. The polymeric matrix has a core of biodegradable, hydrophobic polymer, and an outer shell of a biodegradable, hydrophobic polymer. Alternately, the formulations contain insulin, a polymeric matrix, and a histone.Type: GrantFiled: May 26, 2000Date of Patent: August 21, 2007Inventors: Iouri Tikhosovich Kalinin, Anatoly Borisovich Davydov, Boris Ivanovich Leoniv, Tatjana Igorevna Solodkaya, Gennadiy Ljvovich Khromov, Iouri Gennadievich Bobkov
-
Patent number: 7211275Abstract: Composite materials comprising a water-soluble compound adsorbed onto a basic inorganic material and a bio-degradable polymer which yields acidic degradation products, methods of producing same, and methods of use thereof are described, wherein the composite materials are designed so as to provide controlled release of the water soluble molecule.Type: GrantFiled: January 13, 2005Date of Patent: May 1, 2007Assignee: Massachusetts Institute of TechnologyInventors: Jackie Y. Ying, Tseh-Hwan Yong
-
Patent number: 7201921Abstract: The invention herein relates to a pharmaceutical composition containing loratadine and derivatives thereof which is suitable for use in soft capsule dosage forms. A pharmaceutical composition according to the invention comprises loratadine and derivatives thereof in a pharmaceutically effective amount; and a solvent system comprising a mixture of medium chain fatty acids. The loratadine compositions exhibit good solubility and storage stability while maintaining bioavailability of the drug. The compositions also permit high concentrations of solubilized loratadine per total fill volume and thereby permit the use of smaller capsules to deliver the same dosage of drug.Type: GrantFiled: March 10, 2003Date of Patent: April 10, 2007Assignee: R.P. Scherer Technologies, Inc.Inventors: Jing Lin, Hung Truong
-
Patent number: 7195769Abstract: A pharmaceutical composition of anti-tubercular drugs for oral use comprising Rifampicin and/or Isoniazid wherein the bioavailability of Rifampicin and/or other drugs is enhanced. Preferably the bioavailability of Rifampicin is enhanced by preventing its degradation caused by presence of Isoniazid. Rifampicin and/or Isoniazid may be present in delayed release and/or extended release form such that minimal amount of the drug is dissolved between pH 1 and 4. preferably delayed release of Rifampicin and/or Isoniazid is achieved by treating the drugs with pH sensitive polymers.Type: GrantFiled: April 10, 2001Date of Patent: March 27, 2007Assignee: Panacea Biotec LimitedInventors: Amarjit Singh, Rajesh Jain
-
Patent number: 7163694Abstract: Bioerodible poly(ortho esters) useful as orthopedic implants or vehicles for the sustained delivery of pharmaceutical, cosmetic and agricultural agents from dioxane-based di(ketene acetals). Block copolymers contain these bioerodible poly(ortho esters). These block copolymers have both hydrophilic and hydrophobic blocks. They form micelles in aqueous solution, making them suitable for encapsulation or solubilization of hydrophobic or water-insoluble materials; and they also form bioerodible matrices for the sustained release of active agents.Type: GrantFiled: March 8, 2006Date of Patent: January 16, 2007Assignee: A.P. Pharma, Inc.Inventors: Jorge Heller, Steven Y. Ng
-
Patent number: 7160559Abstract: The present invention is concerned with controlled release compositions for oral administration comprising galantamine; and with processes of preparing such controlled release compositions.Type: GrantFiled: December 20, 1999Date of Patent: January 9, 2007Assignee: Janssen Pharmaceutica N.V.Inventors: John Paul McGee, Paul Marie Victor Gilis, Marc Maurice Germain De Weer, Valentin Florent Victor de Condé, Herman Johannes Catherina de Bruijn, Frederic Anne Rodolf Van Dycke
-
Patent number: 7157095Abstract: An anti-fungal product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-fungal product being reached in less than about twelve hours after initial release of anti-fungal from the product.Type: GrantFiled: August 2, 2002Date of Patent: January 2, 2007Assignee: Advancis Pharmaceutical CorporationInventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
-
Patent number: 7101574Abstract: The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables enhanced bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent.Type: GrantFiled: July 7, 2000Date of Patent: September 5, 2006Assignee: Laboratoires des Produits Ethiques EthypharmInventors: Bruno Criere, Pascal Suplie, Philippe Chenevier
-
Patent number: RE42096Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one of a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.Type: GrantFiled: March 24, 2005Date of Patent: February 1, 2011Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Rong-Kun Chang, Donald J. Treacy, Charlotte M. McGuiness, Edward M. Rudnic